Effect of Cilostazol Administration on Cerebral Hemodynamics and Rehabilitation Outcomes in Poststroke Patients

REFERENCES

• Adams, H. P., Jr., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., (1993). Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 24, 35–41.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. (2002). Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal, 324, 71–86.
   PubMed Web of Science ®Google Scholar
• Bhatt, D. L., Steg, P. G., Ohman, E. M., Hirsch, A. T., Ikeda, Y., Mas, J. L., (2006). REACH registry investigators: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. The Journal of the American Medical Association, 295, 180–189.
   PubMed Web of Science ®Google Scholar
• Brunnstrom, S. (1970). Movement Therapy in Hemiplegia: A Neurophysiological Approach. New York: Harper & Row.
   Google Scholar
• Folstein, M. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189.
   PubMed Web of Science ®Google Scholar
• Gordon, D. L., Bendixen, B. H., Adams, H. P., Jr., Clarke, W., Kappelle, L. J., & Woolson, R. F. (1993). Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: Implications for clinical trials. The TOAST Investigators. Neurology, 43, 1021–1027.
   PubMed Web of Science ®Google Scholar
• Goto, S. (2005). Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis Supplements, 6, 3–11.
   PubMed Web of Science ®Google Scholar
• Gotoh, F., Tohgi, H., Hirai, S., Terashi, A., Fukuuchi, Y., Otomo, E., (2000). Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. Journal of Stroke and Cerebrovascular Disease, 9, 147–157.
   PubMedGoogle Scholar
• Guo, J. J., Xu E., Lin Q. Y., Zeng G. L., Xie H. F. (2009). Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Neuroscience Bulletin, 25, 383–390.
   PubMed Web of Science ®Google Scholar
• Gur, D., Yonas, H., & Good, W. F. (1989). Local cerebral blood flow by xenon-enhanced CT: Current status, potential improvements, and future directions. Cerebrovascular and Brain Metabolism Reviews, 1, 68–86.
   PubMedGoogle Scholar
• Howanitz, E. M., Wisotzek, I. E., Losonczy, M. F., & Schaffer, C. (2001). The relationship between mental status examination scores and cerebral blood flow in geriatric schizophrenia. Schizophrenia Research, 49, 228–229.
   PubMed Web of Science ®Google Scholar
• Huang, Y., Cheng Y., Wu J., Li Y., Xu E., Hong Z., et al. (2008). Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study. Lancet Neurology, 7, 494–499.
   PubMed Web of Science ®Google Scholar
• Jorgensen, H. S., Nakayama, H., Raaschou, H. O., Vive-Larsen, J., Stolier, M., & Olsen, T. S. (1995). Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen stroke study. Archives of Physical Medicine and Rehabilitation, 76, 406–412.
   PubMed Web of Science ®Google Scholar
• Kim, K. Y., Shin, H. K., Choi, J. M., & Hong, K. W. (2002). Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. The Journal of Pharmacology and Experimental Therapeutics, 300, 709–715.
   PubMed Web of Science ®Google Scholar
• Kim, M. J., Park, K. G., Lee, K. M., Kim, H. S., Kim, S. Y., Kim, C. S., (2005). Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension, 45, 552–556.
   PubMed Web of Science ®Google Scholar
• Kitagawa, K., Oku, N., Kimura, Y., Yagita, Y., Sakaguchi, M., Hatazawa, J., (2009). Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. Hypertension Research, 32, 816–820.
   PubMed Web of Science ®Google Scholar
• Kitagawa, Y., Meyer, J. S., Tachibana, H., Mortel, K. F., & Rogers, R. L. (1984). CT-CBF correlation of cognitive deficits in multi-infarct dementia. Stroke, 15, 1000–1009.
   PubMed Web of Science ®Google Scholar
• Kobayashi, S., Yamaguchi, S., Katsube, T., Kitani, M., Okada, K., & Tsunematsu, T. (1985). Long-term effect of Cilostazol on cerebral blood flow in chronic cerebral infarction. Arzneimittel-Forschung/Drug Research, 35(II), 1193–1197.
   Google Scholar
• Kohda, N., Tani, T., Nakayama, S., Adachi, T., Marukawa, K., Ito, R., (1999). Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thrombosis Reserch, 15, 261–268.
   Google Scholar
• Kretschmann, H. J., & Weinrich, W. (1986). Neuroanatomy and Cranial Computed Tomography. New York: Thieme.
   Google Scholar
• Mahoney, F., & Barthel, D. (1965). Functional evaluation: The Barthel index. Maryland State Medical Journal, 14, 61.
   PubMedGoogle Scholar
• Meyer, J. S., Shinohara, T., Imai, A., Kobari, M., Sakai, F., Hata, T., (1988). Imaging local cerebral blood flow by xenon-enhanced computed tomography: Technical optimization procedures. Neuroradiology, 30, 283–292.
   PubMed Web of Science ®Google Scholar
• Moriwaki, H., Uno, H., Nagakane, Y., Hayashida, K., Miyashita, K., & Naritomi, H. (2004). Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stoke. Journal of Human Hypertension, 18, 693–699.
   PubMed Web of Science ®Google Scholar
• Nickman, N. A., Biskupiak, J., Creekmore, F., Shah, H., & Brixner, D. I. (2007). Antiplatelet medication management in patients hospitalized with ischemic stroke. American Journal of Health-System Pharmacy, 64, 2250–2256.
   Google Scholar
• Nogami, K., Fujii, M., Kato, S., Nishizaki, T., Suzuki, M., Yamashita, S., (2004). Analysis of magnetic resonance imaging (MRI) morphometry and cerebral blood flow in patients with hypoxic-ischemic encephalopathy. Journal of Clinical Neuroscience, 11, 376–380.
   PubMed Web of Science ®Google Scholar
• Ogasawara, K., Ogawa, A., Terasaki, K., Shimizu, H., Tominaga, T., & Yoshimoto, T. (2002). Use of cerebrovascular reactivity in patients with symptomatic major cerebral artery occlusion to predict 5-year outcome: Comparison of xenon-133 and iodine-123-IMP single-photon emission computed tomography. Journal of Cerebral Blood Flow and Metabolism, 22, 1142–1148.
   PubMed Web of Science ®Google Scholar
• Oishi, M., Mochizuki, Y., Shikata, E., & Mizutani, T. (2000). Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation. The Keio Journal of Medicine, 49(Suppl 1), A145–A147.
   Google Scholar
• Okudaira, Y., Nakanishi, H., Arai, H., & Sato, K. (2003). Differences in acetazolamide vasoreactivity in patients with acute and chronic occlusion of the internal carotid artery. Journal of Clinical Neuroscience, 10, 316–319.
   PubMed Web of Science ®Google Scholar
• Pindzola, R. R., Balzer, J. R., Nemoto, E. M., Goldstein, S., & Yonas, H. (2001). Cerebrovascular reserve in patients with carotid occlusive disease assessed by stable xenon-enhanced CT cerebral blood flow and transcranial Doppler. Stroke, 32, 1811–1817.
   PubMed Web of Science ®Google Scholar
• Rogers, R. L., Meyer, J. S., Mortel, K. F., Mahurin, R. K., & Judd, B. W. (1986). Decreased cerebral blood flow precedes multi-infarct dementia, but follows senile dementia of Alzheimer type. Neurology, 36, 1–6.
   PubMed Web of Science ®Google Scholar
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., (2006). Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on stroke co-sponsored by the council on cardiovascular radiology and intervention. The American Academy of Neurology affirms the value of these guidelines. Stroke, 37, 577–617.
   PubMed Web of Science ®Google Scholar
• Seta, T., Komaba, Y., Fukuchi, T., Katsura, K., & Katayama, Y. (2004). Effects of cilostazol on serum β-thromboglobulin, platelet factor 4 and cerebral blood flow in the patients with lacunar stroke (in Japanese, abstract in English). No Jyunkan Taisha, 16, 159–166.
   Google Scholar
• Shinohara, Y. (2006). Regional differences in incidence and management of stroke–is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovascular Disease, 21(Suppl), 17–24.
   Google Scholar
• Shinohara, Y., Katayama, Y., Uchiyama, S., Yamaguchi, T., Handa, S., Matsuoka, K., (2010). Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurology, 9, 959–968.
   PubMed Web of Science ®Google Scholar
• Shinohara, Y., & Yamaguchi, T. (2008). Outline of the Japanese guidelines for the management of stroke 2004 and subsequent revision. International Journal of Stroke, 3, 55–62.
   PubMed Web of Science ®Google Scholar
• Takahashi, S., Oida, K., Fujiwara, R., Maeda, H., Hayashi, S., Takai, H., (1992). Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of smooth muscle cell culture. Journal of Cardiovascular Pharmacology, 20, 900–906.
   PubMed Web of Science ®Google Scholar
• Tanaka, T., Ishikawa, T., Hagiwara, M., Onoda, K., Itoh, H., & Hidaka, H. (1988). Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology, 36, 313–320.
   PubMed Web of Science ®Google Scholar
• Tomura, N., Sasaki, K., Kidani, H., Nishii, T., Yasuda, K., Ishiyama, K., (2007). Reduced perfusion reserve in leukoaraiosis demonstrated using acetazolamide challenge 123I-IMP SPECT. Journal of Computer Assisted Tomography, 31, 884–887.
   PubMed Web of Science ®Google Scholar
• Torigoe, R., Hayashi, T., Anegawa, S., Furukawa, Y., Tomokiyo, M., & Katsuragi, M. (1998). Effects of long-term administration of cilostazol on chronic cerebral circulatory insufficiency (in Japanese, abstract in English). No To Shinkei, 50, 829–839.
   Google Scholar
• Uchiyama, S., Demaerschalk, B. M., Goto, S., Shinohara, Y., Gotoh, F., Stone, W. M., (2009). Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials. Journal of Stroke and Cerebrovascular Disease, 18, 482–490.
   PubMedGoogle Scholar
• Uchiyama, S., Nakamura, T., Yamazaki, M., Kimura, Y., & Iwata, M. (2006). New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovascular Disease, 21(Suppl), 7–16.
   Google Scholar
• Ullman, J. S., & Bederson, J. B. (1996). Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? Yes. Critical Care Clinics, 12, 697–707.
   PubMed Web of Science ®Google Scholar
• van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19, 604–607.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2002). The world health report 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization. http://www.who.int/whr/2002/en
   Google Scholar
• Yashiro, Y., & Ohashi, T. (2002). Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. The Japanese Journal of Physiology, 52, 471–477.
   Google Scholar